Karus Therapeutics Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Karus Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013978
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Karus Therapeutics Ltd (Karus) is a designer and developer of molecule cancer therapies. The company provides treatment of a diverse range of solid and hematological cancers and small molecule drug. It develops two clinic-tracked programs potent and selective inhibitors of PI3K and HDAC for the treatment of inflammatory disease. Karus develops and markets medicines based on the potent and isoform-selective inhibition of two enzyme families such as histone deacetylase and PI3 kinase. The company’s development programs offer medical needs in the fields of chronic inflammation, retaining drug design, immunotherapeutic modes, haematological malignancies and solid tumours. Its HDAC6 inhibitors are anti-tumour agents for the treatment of multiple myeloma. Karus is headquartered in Oxford, the UK.

Karus Therapeutics Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Karus Therapeutics Raises US$7 Million In First Tranche Of Series B Financing 10
Partnerships 12
Karus Therapeutics Enters into Agreement with University of Texas MD Anderson Cancer Center 12
Babraham Institute And Karus Therapeutics To Explore PI3 Kinase Inhibitors In Treatment of Inflammatory Diseases 13
Karus Therapeutics Ltd – Key Competitors 14
Karus Therapeutics Ltd – Key Employees 15
Karus Therapeutics Ltd – Locations And Subsidiaries 16
Head Office 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Karus Therapeutics Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Karus Therapeutics Raises US$7 Million In First Tranche Of Series B Financing 10
Karus Therapeutics Enters into Agreement with University of Texas MD Anderson Cancer Center 12
Babraham Institute And Karus Therapeutics To Explore PI3 Kinase Inhibitors In Treatment of Inflammatory Diseases 13
Karus Therapeutics Ltd, Key Competitors 14
Karus Therapeutics Ltd, Key Employees 15

★海外企業調査レポート[Karus Therapeutics Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SIFI SpA-製薬・医療分野:企業M&A・提携分析
    Summary SIFI SpA (SIFI) is an integrated ophthalmic company that focuses on eye care products. It develops, manufactures and markets pharmaceutical products, diagnostic instruments and surgical equipment for the prevention and treatment of the most common ocular pathologies. SIFI develops its produc …
  • Fuller, Smith & Turner Plc:企業の戦略・SWOT・財務情報
    Fuller, Smith & Turner Plc - Strategy, SWOT and Corporate Finance Report Summary Fuller, Smith & Turner Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Commonwealth Bank of Australia:企業のM&A・事業提携・投資動向
    Commonwealth Bank of Australia - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Commonwealth Bank of Australia Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Almac Group Ltd:企業のM&A・事業提携・投資動向
    Almac Group Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Almac Group Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • InnoMedica Holding AG:製薬・医療:M&Aディール及び事業提携情報
    Summary InnoMedica Holding AG (InnoMedica) discovers and develops therapeutics for the treatment of cancer. The company develops drugs using its proprietary drug delivery technology, Talidox, based on the transport and release of active pharmaceutical agents, locally, at the target area. Its pipelin …
  • CapeRay Medical (Pty) Ltd:製品パイプライン分析
    Summary CapeRay Medical (Pty) Ltd (CapeRay), formerly African Medical Imaging is a medical device company that offers imaging solutions. The company offers breast imaging devices. It offers aceso system to detect breast cancer with standard digital mammography. CapeRay’s aceso system is used for det …
  • GFH Financial Group BSC (GFH):企業の財務・戦略的SWOT分析
    GFH Financial Group BSC (GFH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Obuv Rossii OOO (OBUV):企業の財務・戦略的SWOT分析
    Obuv Rossii OOO (OBUV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Abzena Plc (ABZA):製薬・医療:M&Aディール及び事業提携情報
    Summary Abzena Plc (Abzena), formerly Polytherics Group Ltd, is a life science company that provides complementary services and technologies to enable the selection, development and manufacture of biopharmaceuticals products based on antibodies and other proteins. The company's technologies include …
  • AirStrip Technologies Inc:医療機器:M&Aディール及び事業提携情報
    Summary AirStrip Technologies Inc (AirStrip) is a healthcare solution provider that offers medical software solutions and services. The company offers mobile interoperability platform interoperability platform that offers access to critical patient data and intelligent insights across the care conti …
  • Hanwha Chemical Corp (009830):企業の財務・戦略的SWOT分析
    Summary Hanwha Chemical Corp (Hanwha), a subsidiary of Hanwha Corp is a chemical company that manufactures, develops, and distributes basic industrial chemicals, general purpose plastic products, and other chemical products. The company's chemical products include inorganic compounds, PVC, polymers, …
  • Mckesson Europe AG.:企業の戦略・SWOT・財務情報
    Mckesson Europe AG. - Strategy, SWOT and Corporate Finance Report Summary Mckesson Europe AG. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Moog Inc (MOG.A):企業の財務・戦略的SWOT分析
    Moog Inc (MOG.A) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Ominto Inc (OMNT):企業の戦略的SWOT分析
    Ominto Inc (OMNT) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • American Electric Power Company, Inc. (AEP)-エネルギー分野:企業M&A・提携分析
    Summary American Electric Power Company, Inc. (AEP) is a holding company that carries out the generation, transmission and distribution of electricity through its subsidiaries. The company generates electricity through various sources of energy such as coal and lignite, natural gas, nuclear, and hyd …
  • K2M Inc-医療機器分野:企業M&A・提携分析
    Summary K2M Inc (K2M), a subsidiary of K2M Group Holdings Inc is a medical device company that designs, develops and markets spine solutions products for the treatment of spinal pathologies. The company offers complex spine, minimally invasive, degenerative and biologics products. It offers complex …
  • SGL Carbon SE:企業の戦略・SWOT・財務分析
    SGL Carbon SE - Strategy, SWOT and Corporate Finance Report Summary SGL Carbon SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Strayer Education Inc (STRA):企業の財務・戦略的SWOT分析
    Summary Strayer Education Inc (Strayer) operates as an educational service provider that offers undergraduate and graduate degree programs. The institute’s degree programs include business administration, accounting, information technology, education, health services administration and public admini …
  • SunPower Corporation (SPWR):電力:M&Aディール及び事業提携情報
    Summary SunPower Corporation (SunPower), a subsidiary of Total Solar International SAS, is a provider of solar technology and energy services. The company has a presence in solar value chain from cell and panel manufacturing, project development, project finance through engineering, procurement, and …
  • Duravit AG:企業の戦略・SWOT・財務情報
    Duravit AG - Strategy, SWOT and Corporate Finance Report Summary Duravit AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆